In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $62.00. The company’s shares closed last Friday at $13.78.
Arce covers the Healthcare sector, focusing on stocks such as Akebia Therapeutics, Assembly Biosciences, and Pliant Therapeutics. According to TipRanks, Arce has an average return of 10.0% and a 40.16% success rate on recommended stocks.
Akero Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $26.98 and a one-year low of $7.52. Currently, Akero Therapeutics has an average volume of 397K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Read More on AKRO:
- H.C. Wainwright Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
- H.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)
- Benchmark Co. Reaffirms Their Hold Rating on Western Digital (WDC)
- Needham Remains a Buy on Revolve Group (RVLV)
- Wall Street Analysts Are Neutral on Top Healthcare Picks
